Related Experiment Video
Updated: Aug 10, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
[Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma]
Objective:
To assess the optinums chemotherapeutic protocols for higher CR rate in the treatment of intermediate and high grade malignant non Hodgin's lyphoma(NHL).
Methods:
Seventy-four patients with pathological intermediate and high grade malignant NHL were tried randomly with revised ProMACE-CytaBOM(treatment group) and CHOP(control group).
Results:
The CR rate was 56.8% in the treatment group and 35.0% in the control group (P > 0.05). In patients with high grade maliganat NHL, the CR rate of ProMACE-CytaBOM was 60.0% as compared with 32.0% of the CHOP (P < 0.05). Patients in both group suffered from similar side effects with tolerable bone marrow supression and gastric irritation.
Conclusion:
ProMACE-CytaBOM is a safe regimen with relative high CR rate for high grade malignant NHL, but further research is indicated for remote results.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy

